Weijing Sun, MD
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Director of GI Medical Oncology, Division of Hematology-Oncology Dept of Medicine, Abramson Cancer Center
Department: Medicine
Contact information
16 Penn Tower
3400 Spruce Street
Philadelphia, PA 19104-4283
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 215-662-6018, 662-7964
Fax: 215-662-2432
Fax: 215-662-2432
Email:
weijing.sun@uphs.upenn.edu
weijing.sun@uphs.upenn.edu
Education:
MD
Shanghai Medical University (It has been merged with Fudan University recently), Shanghai, China, 1982.
MS
University of Nebraska, Lincoln, Nebraska, 1991.
MD
Shanghai Medical University (It has been merged with Fudan University recently), Shanghai, China, 1982.
MS
University of Nebraska, Lincoln, Nebraska, 1991.
Post-Graduate Training
Staff, Shanghai Medical University, Shanghai, China, 1983-1987.
Graduate Student , University of Nebraska, School of Life Sciences, Lincoln, Nebraska, 1987-1991.
Post-doctoral Researcher, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, 1991-1995.
Intern in Medicine, Loyola University Medical Center, Maywood, Illinois, 1995-1996.
Resident in Medicine, Loyola University Medical Center Maywood, Illinois, 1996-1998.
Fellow in Hem/Onc, University of Pennsylvania, Philadelphia, Pennsylvania, 1998-2001.
Staff, Shanghai Medical University, Shanghai, China, 1983-1987.
Graduate Student , University of Nebraska, School of Life Sciences, Lincoln, Nebraska, 1987-1991.
Post-doctoral Researcher, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, 1991-1995.
Intern in Medicine, Loyola University Medical Center, Maywood, Illinois, 1995-1996.
Resident in Medicine, Loyola University Medical Center Maywood, Illinois, 1996-1998.
Fellow in Hem/Onc, University of Pennsylvania, Philadelphia, Pennsylvania, 1998-2001.
Certifications
Internal Medicine Board Certification , 1998.
Medical Oncology Board Certification, 2001.
Permanent linkInternal Medicine Board Certification , 1998.
Medical Oncology Board Certification, 2001.
Description of Research Expertise
Clinical investigation of new drug development in cancer treatment/therapy.Member of NCI GISC, Hepatobiliary Cancer Task Force Committee
ECOG GI Core Committee Member
Description of Clinical Expertise
National and reginal expert in the treatment/therapy of GI cancers: esophageal, gastric, pancreatic, hepatic, biliary, colorectal, and neuoendocrin cancers...Commitee member of National Continue Medical Education.
Description of Other Expertise
Visitiong Professorship in China, Traning oncologists oversea. Have trained (invited) 8 oncologists/experties (at associate professor level) on Penn as vistiong schoolars (3 months each term)Selected Publications
Sun W, Whittington R, Gallagher M, O’Dwyer P, Giantonia B, Metz J, and Haller D. : Two Phase I Combined Modality Studies of Concurrent Radiotherapy (XRT) With Continuous Infusion 5-FU, Epirubicin and Cisplatin (ECF) or Irinotecan (EIF) for Locally Advanced Upper GI Adenocarcinoma. Oncology (Huntint) 15(4): 430-434, 2004.Vertonese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio B, Hahn S Vaughn D, Thorn C, Whitehead AS, Haller D, O’Dwyer PJ. : Phase I trial of UFT/leucovorin in patients with advanced cancer. Euro J Cancer 40(4): 508-14, 2004.
Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantoio B, Zimmer R, Petros W, Stratford M, Chaplin D, Young SL, Schnall M, O’Dwyer PJ: Phase I trial of the antivascular agent combretastain A4 phosephate on a five-day schedule to patients with cancer: MRI evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438, 2003.
Sun W, Theobald M, Hershock D, Haller DG. : A phase I combination trial of fixed-dose-rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Gastrointestinal Cancers Symposium 1: 107a (A132), 2004 Notes: poster presentation.
Zac T, Sun, W. : Cancer of large bowel and hepatobiliary tract. Cancer Chemotherapy & Biological Response Modifiers. Giaccone, Schilsky and Sondi eds, (eds.). Annual 22: 443-470, 2005.
Sun W, Stevenson JP, Gallagher M, Vaughn D, Hahn SM, Haller DG, Gallant G, and O’Dwyer PJ. : Phase I and pharmacokinetic trial of BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res 9(14): 5221-5227, 2003.
Sun W., Rustgi AK. : Esophageal Neoplasms. Textbook of Gastroenterology, 4th ed. Tadataka Yamada (eds.). Lippincott Williams & Wilkins, Page: 24 (1238-1261), 2003.
Sun, W., Haller D.: Cancer of large bowel and hepatobiliary tract. Cancer Chemotherapy & Biological Response Modifiers. Annual 21. Giaccone, Schilsky and Sondi (eds.). 2003.
d’Entremont TC, Sun, W. : Recent advances in colorectal cancer therapy. Cancer Biology & Therapy 2(1): 6-13, 2003.
Sun, W., and Haller D.: Gastrointestinal Cancer. WebMD Scientific American of Medicine, ACP Medicine. A Publication of the American College of Physicians. David C. Dale, Daniel D. Federman (eds.). WebMD Scientific American of Medicine, 2004-2005 Edition: 2423-2444, 2004.
